'What is the risk to me from COVID-19?': Public involvement in providing mortality risk information for people with 'high-risk' conditions for COVID-19 (OurRisk.CoV).

Autor:	Banerjee A; University College London, London, UK, honorary consultant cardiologist, University College London Hospitals NHS Trust, London, UK, and honorary consultant cardiologist, Barts Health NHS Trust, London, UK ami.banerjee@ucl.ac.uk., Pasea L; University College London, London, UK., Manohar S; Health Data Research UK, London, UK., Lai AG; University College London, London, UK, and associate, Health Data Research UK, London, UK., Hemingway E; Flourish, London, UK., Sofer I; AllBright, London, UK., Katsoulis M; University College London, London, UK., Sood H; Health Education England, London, UK, and general practitioner, Hurley Group Practice, London, UK., Morris A; Health Data Research UK, London, UK., Cake C; Health Data Research UK, London, UK., Fitzpatrick NK; University College London, London, UK, and associate, Health Data Research UK, London, UK., Williams B; University College London Hospitals NHS Trust, London, UK, professor of medicine, University College London, London, UK, and director, UCL Hospitals NIHR Biomedical Research Centre., Denaxas S; University College London, London, UK, associate, Health Data Research UK, and research fellow, Alan Turing Institute, London, UK., Hemingway H; University College London, London, UK, research director, Health Data Research UK, London, UK, and director of healthcare informatics, genomics/omics, data science, UCL Hospitals NIHR Biomedical Research Centre, London, UK.
Jazyk:	angličtina
Zdroj:	Clinical medicine (London, England) [Clin Med (Lond)] 2021 Nov; Vol. 21 (6), pp. e620-e628.
DOI:	10.7861/clinmed.2021-0386
Abstrakt:	Patients and public have sought mortality risk information throughout the pandemic, but their needs may not be served by current risk prediction tools. Our mixed methods study involved: (1) systematic review of published risk tools for prognosis, (2) provision and patient testing of new mortality risk estimates for people with high-risk conditions and (3) iterative patient and public involvement and engagement with qualitative analysis. Only one of 53 (2%) previously published risk tools involved patients or the public, while 11/53 (21%) had publicly accessible portals, but all for use by clinicians and researchers.Among people with a wide range of underlying conditions, there has been sustained interest and engagement in accessible and tailored, pre- and postpandemic mortality information. Informed by patient feedback, we provide such information in 'five clicks' (https://covid19-phenomics.org/OurRiskCoV.html), as context for decision making and discussions with health professionals and family members. Further development requires curation and regular updating of NHS data and wider patient and public engagement. (© Royal College of Physicians 2021. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu Plný text ve formátu PDF